Results 161 to 170 of about 36,304 (249)

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos S. Mantzoros   +4 more
wiley   +1 more source

The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review. [PDF]

Int J Mol Sci
Yamanouchi D.
europepmc   +1 more source

Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Shokravi A, Seth J, Lu N, Mancini GBJ.
europepmc   +1 more source

Emerging Regulatory Mechanisms in Sinoatrial Node Automaticity

Journal of Cellular and Molecular Medicine, Volume 30, Issue 4, February 2026.
ABSTRACT The sinoatrial node (SAN), the primary cardiac pacemaker, governs rhythmic heartbeats through spontaneous electrical impulses. While the classical “coupled‐clock” theory, integrating the membrane voltage clock (driven by cyclic ion channel activity) and the calcium clock (orchestrated by rhythmic sarcoplasmic reticulum Ca2+ release), remains ...
Hongyu Liu, Yuting Cao, Xuling Su
wiley   +1 more source

Defining the Intestinal eCBome and Oxylipin Signaling Systems in a TDP‐43 Mouse Model of Frontotemporal Dementia

The FASEB Journal, Volume 40, Issue 2, 31 January 2026.
TDP‐43 overexpressing mice, a genetic model of frontotemporal dementia, exhibit dramatic changes in their small intestinal endocannabinoidome members, in terms of both altered concentrations of lipid mediators and expression of some of their receptors (Cnr1, Gpr119, Gpr55, Pparg) and metabolic enzymes (Napepld, Faah). Also, the levels of some oxylipins
Hayatte‐Dounia Mir, Giada Giorgini, Irene Santos‐García, Elizabeth Dumais, Carmen Rodríguez‐Cueto, Eva de Lago, Cristoforo Silvestri, Nicolas Flamand, Javier Fernández‐Ruiz, Vincenzo Di Marzo   +9 more
wiley   +1 more source

The Future of Obesity Management: Bridging Pharmacologic Innovation and Public Health. [PDF]

Diabetes Metab Syndr Obes
Qian F, Wang L.
europepmc   +1 more source

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Frontiers in Endocrinology, 2019
Carolyn F. Deacon
doaj   +1 more source

Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States

Diabetes, Metabolic Syndrome and Obesity
Sriya Amruta Kosaraju,1 Rong M Zhang2 1Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA; 2Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence: Rong M Zhang ...
Kosaraju SA, Zhang RM
doaj  

Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy. [PDF]

Amino Acids
Fajkić A, Lam YW, Belančić A.
europepmc   +1 more source

Associations between Eating Behaviours and Psychological Characteristics with Body Mass Index Change and Appetite-Related Changes during Incretin-Based Therapy. [PDF]

Obes Facts
Kapan A, Haider S, Moser O, Waldhoer T, Felsinger R.   +4 more
europepmc   +1 more source